MADRIGAL PHARMACEUTICALS INC
For the period ended Dec 31, 2024. Filed Feb 26, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 26, 2025
MDGL$432.60-0.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
| Year Ended December 31, | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Cash flows from operating activities: | |||
| Net loss | $(465,892) | $(373,630) | $(295,350) |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||
| Stock-based compensation expense | 79,880 | 49,735 | 31,625 |
| Depreciation and amortization expense | 1,096 | 527 | 467 |
| Amortization of debt issuance costs and discount | 2,089 | 2,414 | 797 |
| Amortization and interest accretion related to operating leases | (400) | — | — |
| Changes in operating assets and liabilities: | |||
| Trade receivables, net | (53,822) | — | — |
| Inventory | (34,068) | — | — |
| Prepaid expenses and other current assets | (10,636) | (555) | (1,257) |
| Accounts payable | 15,558 | 4,210 | 2,451 |
| Accrued liabilities | 34,715 | (1,481) | 36,413 |
| Accrued interest, net of interest received on maturity of investments | (24,092) | (5,450) | (3) |
| Net cash used in operating activities | (455,572) | (324,230) | (224,857) |
| Cash flows from investing activities: | |||
| Purchases of marketable securities | (1,131,207) | (834,439) | (143,478) |
| Sales and maturities of marketable securities | 863,283 | 333,398 | 350,381 |
| Acquisition of intangible asset | (5,000) | — | — |
| Purchases of property and equipment, net of disposals | (1,462) | (1,479) | (217) |
| Net cash provided by (used in) investing activities | (274,386) | (502,520) | 206,686 |
| Cash flows from financing activities: | |||
| Proceeds from issuances of stock, excluding related parties, net of transaction costs | 397,487 | 260,187 | 255,382 |
| Proceeds from related parties - warrants, exercise of common stock options, net of transaction costs | 337,575 | 270,292 | 8,955 |
| Proceeds from issuance of loan payable | — | 65,000 | 50,000 |
| Payment of debt issuance costs | — | (363) | (886) |
| Net cash provided by financing activities | 735,062 | 595,116 | 313,451 |
| Net increase (decrease) in cash and cash equivalents | 5,104 | (231,634) | 295,280 |
| Cash, cash equivalents, and restricted cash at beginning of period | 99,915 | 331,549 | 36,269 |
| Cash, cash equivalents, and restricted cash at end of period | $105,019 | $99,915 | $331,549 |
| Supplemental disclosure of cash flow information: | |||
| Obtaining a right-of-use asset in exchange for a lease liability | $1,330 | $1,628 | $583 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.